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Pyrrolocytosines RX-04A-D are designed to bind to the bacterial 50S ribosomal 30 
subunit differently from currently-used antibiotics.  The four analogs had 31 
broad anti-Gram-negative activity: RX-04A inhibited 94.7% of clinical 32 
Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa 33 
at 0.5-4 g/ml, with no MICs >8 g/ml. MICs for multi-resistant carbapenemase 34 
producers were up to two-fold higher than for control strains, with values >8 35 
g/ml for one Serratia isolate with porin and efflux lesions.  mcr-1 did not 36 
affect MICs. 37 
 38 
One approach in the search for new antibacterial agents is to model the target 39 
interactions of natural antibiotics that are unsuitable for pharmaceutical development, 40 
owing to toxicity or instability, and to use this information to design synthetic 41 
molecules that achieve similar binding without the unfavorable traits of the original 42 
compounds.   43 
Melinta Pharmaceuticals has applied this strategy to blasticidin S, a natural 44 
product of Streptomyces griseochromogenes that inhibits both eukaryotic and 45 
prokaryotic ribosomes but which has proved useful only as a fungicide, deployed to 46 
control rice blast disease in Japan [1].  Modelling of the ribosomal interactions of 47 
blasticidin [2], TAB-1057A/B [3] and amecitin [4] - which have overlapping targets 48 
that are distinct from those of clinically-used bacterial protein synthesis inhibitors - 49 
had led to several new antibacterial scaffolds, including pyrrolocytosines [5,6]. These 50 
are chemically unrelated to blasticidin, but mimic its principal interactions with the 51 
bacterial 50S subunit [6]. In-vitro antibacterial activity indicates that the 52 
pyrrolocytosines penetrate into bacterial cells, and further development has sought 53 
to optimise this penetration for Gram-negative bacteria whilst reducing vulnerability 54 
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to efflux [5].  Chemical properties of the pyrrolocytosine derivatives along with 55 
synthetic methods, are outlined in the relevant patents [7-9]. 56 
We evaluated four pyrrolocytosine derivatives, RX-04A - D (fig. 1), against a 57 
panel of 96 Gram-negative clinical isolates, biased to over-represent 58 
carbapenemase producers, Enterobacteriaceae with mcr-1 and Pseudomonas 59 
aeruginosa with up-regulated efflux. We additionally tested Escherichia coli HB10B 60 
and its transformant, carrying plasmid p594, which encodes expression of mcr-1 61 
[10]. The mcr-1 and carbapenemase genes were detected by PCR or sequencing 62 
[10,11] whilst efflux levels in P. aeruginosa isolates were inferred by interpretive 63 
reading of antibiograms data, which predicts mechanisms from phenotypes [12].  64 
MICs of the four RX-04 analogs and comparators (amikacin, cefepime, colistin, 65 
meropenem, and tigecycline) were determined by CLSI broth microdilution [13] using 66 
pre-prepared plates (Trek Diagnostic Systems, Thermofisher, Oakwood, OH). DNA 67 
from four Serratia isolates differing in susceptibility to the pyrrolocytosines was 68 
extracted using a QIAsymphony automated instrument. Sequencing libraries were 69 
prepared using the Nextera XT DNA library preparation kit and sequenced on 70 
Illumina HiSeq 2500 system using the 2 x 100-bp paired-end mode. Genomes were 71 
assembled de novo with VelvetOptimiser 2.1.9 software 72 
(http://bioinformatics.net.au/software.velvetoptimiser.shtml) and then compared with 73 
each other to seek genetic modifications that were specific to the Serratia with the 74 
highest pyrrolocytosine MICs, particularly in genes encoding porins, efflux pumps 75 
and the rRNA targets of the pyrrolocytosines. 76 
MICs by species, irrespective of resistance mechanism, are shown in Table 1, 77 
whilst Table 2 shows geometric mean MICs for major resistance types represented 78 
in the test panels. Non-susceptibility rates to comparators for the Enterobacteriaceae 79 
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isolates (n=66), at CLSI breakpoints, were: amikacin 14%, cefepime 50%, colistin 80 
33% (2 g/ml EUCAST breakpoint), meropenem 47%, and tigecycline 15% (1 g/ml 81 
EUCAST breakpoint); those for the same agents against the A. baumannii isolates 82 
(n=10) were amikacin 40%, cefepime 50%, colistin 0%, meropenem 50% and 83 
tigecycline 50%, respectively.  Non-susceptibility rates for the P. aeruginosa isolates 84 
(n=20) were amikacin 15%, cefepime 45%, colistin 25% and meropenem, 45%. 85 
Despite this heavy loading with isolates resistant to established agents, MIC 86 
distributions of RX-04A - D were all unimodal and tightly clustered. MICs were lowest 87 
for RX-04A, where 94.7% of values, for all species pooled, lay between 0.5 and 4 88 
g/ml, with no values greater than 8 g/ml. MICs were highest for analogs RX-04C 89 
and RX-04D, particularly for P. aeruginosa.  Irrespective of the analog, the general 90 
pattern was for MICs to be lowest for E. coli, slightly higher for other 91 
Enterobacteriaceae, particularly Serratia spp., and highest for P. aeruginosa.  92 
 MICs for a single S. marcescens isolate, which also had OXA-48 93 
carbapenemase, were raised markedly, at 8, 16, >16 and >16 g/ml for molecules 94 
RX-04A, B, C and D respectively, compared with 1-2, 1-4, 2-4 and 2-4 g/ml, 95 
respectively, for the remaining three Serratia isolates tested.  Comparison of the four 96 
sequenced genomes revealed the high-MIC isolate to have both (i) a premature stop 97 
codon (Tyr211) in omp2, which is an ompC/F homolog and (ii) multiple unique 98 
changes (as compared with all three low-MIC Serratia isolates) in the sdeCDE 99 
operon, encoding an RND pump system [14], specifically, Asn407Ser, Ser432Asn, 100 
Glu433Ala, Ala437Thr, Ala438Asn, Asn439Lys, Ala440Thr, Glu443Gln, ArgR448Gly 101 
in sdeC, Glu111Asp and Thr363Met in sdeD and Glu240Asp in sdeE.  None of these 102 
changes were observed in the three low-MIC Serratia genomes.   No lesions specific 103 
to the high-MIC isolate were found (i) in other recognised porin genes (omp1 and 104 
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omp3), (ii) in porin regulatory genes (ompR and envZ), (iii) in efflux pump genes 105 
(smdAB, sdeXY, smfY and ssmE), nor (iv) in genes encoding the 16S or 23S rRNA 106 
targets of the RX-04A-D molecules. Inactivation of omp2 seems likely to reduce 107 
pyrrolocytosine uptake and the sdeCDE lesions may increase efflux explaining the 108 
phenotype of the high-MIC Serratia isolate.  These uptake and efflux lesions also are 109 
congruent with an observed meropenem MIC of 32 g/ml, which is unusually high for 110 
an Enterobacteriaceae with an OXA-48 -lactamase. 111 
Geometric mean MICs of the four analogs for carbapenemase-producing 112 
Enterobacteriaceae were slightly above those for the susceptible control strains, 113 
though the differentials never exceeded one doubling dilution (Table 2).  These small 114 
rises again probably reflected widespread reductions in permeability or upregulations 115 
in efflux among the carbapenemase-producing Enterobacteriaceae.  The MIC 116 
differential for carbapenemase-producing versus non-producing A. baumannii was 117 
larger, exceeding two-fold for analogs RX-04B-D, though not for RX-04A; however, 118 
numbers were small and 3/5 OXA-23-producing isolates belonged to the same 119 
lineage (International Clone II [15]) raising the possibility that the mean was skewed 120 
by over-representation of this lineage. 121 
The effect of mcr-1 was of interest because the pyrrolocytosines are polybasic 122 
(fig. 1), raising the hypothetical concern that MCR-1-mediated substitution of 123 
lipopolysaccharides with positively-charged phosphoethanolamine [16] might impede 124 
their initial interaction with the cell surface, reducing uptake.  MICs of the RX analogs 125 
for the mcr-1-positive isolates were around one doubling dilution above those for 126 
control strains. However most (11/14) of these isolates were Salmonella enterica, 127 
being compared with E. coli controls, and the differential may reflect species rather 128 
than mechanism.  Crucially, transformation of E. coli DH10B with the mcr-1–129 
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encoding plasmid p594 had no effect on MICs of RX-04A, B, C and D, which 130 
remained at 0.25, 0.5, 0.5 and 1 g/ml respectively, whereas the MIC of colistin was 131 
raised from 0.25 to 4 g/ml. A caveat is that we do not know the extent of LPS 132 
modification achieved by p594-mediated carriage of mcr-1, nor the mode of 133 
expression, meaning that we cannot definitively exclude the possibility that induction 134 
by the pyrrolocytosines was weaker than by colistin.  This seems unlikely, though: if 135 
LPS-substitution with positively charged alcohols and sugars compromised the 136 
pyrrolocytosines, then generalized resistance would be expected in colistin-resistant 137 
genera such as Serratia, and this was not seen.    138 
In the case of P. aeruginosa, geometric mean MICs of all analogs were ca. 139 
1.5-fold higher for the isolates with ‘normal’ versus low efflux, but did not rise further 140 
for those with elevated efflux-mediated resistance to -lactams and fluoroquinolones 141 
(Table 2).     142 
In conclusion, these data indicate that the four pyrrolocytosine molecules had 143 
broad activity against Enterobacteriaceae and non-fermenters, with RX-04A the most 144 
active analog. Near-full activity was retained against isolates with resistance 145 
mechanisms of current concern, including against carbapenemase producers, those 146 
with mcr-1-mediated colistin resistance and (perhaps most surprisingly) P. 147 
aeruginosa with up-regulated efflux. A caveat is that the strain panel was small and 148 
we cannot exclude the possibility that resistance might arise from novel or 149 
unsuspected mechanisms, only detectable with a larger panel..  Notably, raised 150 
MICs were seen for one Serratia with inactivated omp2 and upregulated sdeCDE 151 
efflux suggesting that combinations of impermeability and up-regulated efflux can 152 
compromise activity, at least against this species.   153 
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Given this spectrum, the new target, and demonstrable activity in 154 
experimental infections [17], the pyrrolocytosine class warrants further evaluation 155 
with a view to possible clinical development. 156 
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Table 1. Pyrrolocytosine MIC distributions by species, irrespective of resistance mechanism 244 
Analog MIC (g/ml) 
 0.25 0.5 1 2 4 8 16 >16 
RX-04A         
E. coli 1 8 14           
S. enterica     11           
K. pneumoniae   2 14 4         
E. cloacae   1 5 2         
Serratia spp.     1 2   1     
P. aeruginosa   1 4 4 10 1     
A. baumannii     3 4 1 2     
All 1 12 52 16 11 4     
                  
RX-04B                 
E. coli 1 6 15 1         
S. enterica     10 1         
K. pneumoniae   1 14 5         
E. cloacae     5 3         
Serratia spp.     1   2   1   
P. aeruginosa   1 3 4 7 2 2 1 
A. baumannii     2 4 3 1     
All 1 8 50 18 12 3 3 1 
                  
RX-04C                 
E. coli 1   12 10         
S. enterica       11         
K. pneumoniae   1 8 6 5       
E. cloacae     1 6 1       
Serratia spp.       1 2     1 
P. aeruginosa   1   4 3 3 6 3 
A. baumannii     3 1 2 4     
All 1 2 24 39 13 7 6 4 
                  
RX-04D                 
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E. coli   1 2 18 2       
S. enterica       11         
K. pneumoniae     2 11 5 2     
E. cloacae     1   5 2     
Serratia spp.       1 2     1 
P. aeruginosa       4   6 7 3 
A. baumannii       2 1 3 4   
All  1 5 47 15 13 11 4 
 245 
 246 
247 
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 248 
Table 2.  Geometric mean MIC (g/ml) for different resistance groups 249 
 n RX-04A RX-04B RX-04C RX-04D 
E. coli, wild type 5 0.5 0.6 0.9 1.3 
E. coli, carbapenemase 15a 0.8 0.9 1.3 2.1 
E. coli/Salmonella, mcr-1 14 b 1.0 1.1 2.0 2.0 
K. pneumoniae, wild type 5 1.0 1.0 1.0 2.0 
K. pneumoniae, carbapenemase 15 a 1.1 1.2 2.0 2.8 
E. cloacae, wild type 4 1.0 1.2 1.7 3.4 
E. cloacae, carbapenemase 4 c 1.2 1.4 2.4 4.8 
Serratia spp., wild type 2  1,2 d 1,4 d 2,4 d 2,4 d 
Serratia spp., carbapenemase 2 e 2,8 d 4,16 d 4,>16 d 4,16 d 
P. aeruginosa, low efflux 5 1.5 1.7 3.5 5.3 
P. aeruginosa, normal efflux/ wild type 5 2.6 3.0 7.0 11.3 
P. aeruginosa, high efflux 5 2.6 3.0 7.0 6.1 
P. aeruginosa, carbapenemase 5 f 3.5 6.7 5.7 12.7 
A. baumannii, wild type 5 1.7 1.7 2.0 4.6 
A. baumannii, OXA-23-positive 5 3.0 3.5 5.3 12.1 
 250 
aFive isolates each with KPC, NDM and OXA-48-like enzymes 251 
b11 S. enterica, 3 E. coli 252 
cTwo isolates with KPC enzymes and single strains with OXA-48 and NDM 253 
d Single isolates with SME and OXA-48-like enzymes 254 
e Since only two isolates were tested, actual MICs are shown, not the mean 255 
f Two isolates with VIM, two with NDM carbapenemases, one with an IMP enzyme256 
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FIGURE 1. RX-04 pyrrolocytosine structures  257 
 258 
 259 
 260 
 261 
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